Across TCGA pan-cancer cohorts, SLC22A25 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC22A25’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC22A25 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC22A25 is over-expressed in tumor, although a few such as KIRC and CHOL show the opposite, repressed pattern.

KIRC, CHOL, and BRCA are the cancer types where SLC22A25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC22A25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.006	.017	5	view →
CHOL	All	All	−3.001	<.001	3	view →
BRCA	All	II,III,IV	−0.050	.013	2	view →
KICH	All	All	+0.310	.024	1	view →
HNSC	All	All	+0.086	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SLC22A25 RNA expression & survival · all SLC22A25 data types